Assessment of availability and efficacy of commercial Salmonella grouping antisera.
AUTOR(ES)
Evins, G M
RESUMO
Salmonella somatic antisera for groups A to E were purchased from four commercial producers directly by the Center for Disease Control (CDC) and indirectly through two hospitals. CDC specifications and methods were used to evaluate antisera shipped directly to CDC. To assess the performance of the products under simulated user conditions, we used the commercial antisera purchased indirectly through the hospitals to group coded cultures. Of the 23 antisera ordered by CDC and the hospitals, the CDC received all 23, a large medical complex received 20, and a private hospital received 9. Similar results were obtained with producer and CDC test methods. Forty-five different lots of antisera were evaluated, of which 20% did not meet CDC specifications. The CDC specifications and latest revisions are discussed.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=275254Documentos Relacionados
- Evaluation of commercial Salmonella O polyvalent and Vi antisera.
- Insolubilized Salmonella lipopolysaccharides as efficient immunoadsorbents for the preparation of specific Salmonella antisera.
- Quality of commercially produced Shigella serogrouping and serotyping antisera.
- Typing of pneumococci by using 12 pooled antisera.
- Cross-reactions of lipopolysaccharides of Pseudomonas aeruginosa in antipneumococcal and other antisera.
